ReviewCurrent pharmaceutical design2009
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.
Review in Current pharmaceutical design, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 47 citations in OpenAlex.
- Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy.The AAPS journal · 2022Article
- Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.Proceedings of the National Academy of Sciences of the United States of America · 2018Review
- Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.Toxins · 2018Article
- Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.Cellular immunology · 2017Article
- Immunogenicity of therapeutic recombinant immunotoxins.Immunological reviews · 2016Review
- Article
- Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines.Journal of medical microbiology · 2015Article
- Cytotoxicity of purified listeriolysin O on mouse and human leukocytes and leukaemia cells.BMC biotechnology · 2014Article
- Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.Gynecologic oncology · 2013Article
- Hairy cell leukemia-new genes, new targets.Current hematologic malignancy reports · 2013Review
- Macrophage-targeted therapy: CD64-based immunotoxins for treatment of chronic inflammatory diseases.Toxins · 2012Review
- In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.Oncology letters · 2012Article
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.Investigational new drugs · 2012Article
- Immunoconjugates and new molecular targets in hairy cell leukemia.Hematology. American Society of Hematology. Education Program · 2012Review
- A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.The FEBS journal · 2011Review
- Toxin-based therapeutic approaches.Toxins · 2010Review
- Targeted treatment and new agents in diffuse large B cell lymphoma.International journal of hematology · 2010Review
- Immunologic mechanisms in RCC and allogeneic renal transplant rejection.Nature reviews. Urology · 2010Review
- Development and scale-up of a commercial fed batch refolding process for an anti-CD22 two chain immunotoxin.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Recombinant immunotoxins are proteins composed of fragments of monoclonal antibodies fused to truncated protein toxins. No agents of this class are approved yet for medical use, although a related molecule, denileukin diftitox, composed of interleukin-2 fused to truncated diphtheria toxin, is approved for relapsed/refractory cutaneous T-cell lymphoma. Recombinant immunotoxins which have been tested in patients with chemotherapy-pretreated hematologic malignancies include LMB-2 (anti-CD25), BL22 (CAT-3888, anti-CD22) and HA22 (CAT-8015, anti-CD22), each containing an Fv fragment fused to truncated Pseudomonas exotoxin. Major responses were observed with LMB-2 in adult T-cell leukemia, chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, Hodgkin's disease, and hairy cell leukemia (HCL). BL22 resulted in a high complete remission rate in patients with HCL, particularly those without excessive tumor burden. HA22, an improved version of BL22 with higher affinity to CD22, is now undergoing phase I testing in HCL, CLL, non-Hodgkin's lymphoma, and pediatric acute lymphoblastic leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.